Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Mikami, H. Kimura, K. Kamiyama, K. Torii, K. Kasuno, Naoki Takahashi, H. Yoshida, M. Iwano (2014)
Telmisartan activates endogenous peroxisome proliferator-activated receptor-δ and may have anti-fibrotic effects in human mesangial cellsHypertension Research, 37
(2015)
From leptin to other adipo - kines in health and disease : facts and expectations at the beginning of the 21 st century
G. Mancia, R. Fagard, K. Narkiewicz, Josep Redán, A. Zanchetti, Michael Böhm, T. Christiaens, R. Cífková, G. Backer, A. Dominiczak, M. Galderisi, D. Grobbee, Tiny Jaarsma, Paulus Kirchof, S. Kjeldsen, S. Laurent, A. Manolis, P. Nilsson, L. Ruilope, R. Schmieder, P. Sirnes, Peter Sleight, M. Viigimaa, Bernard Waeber, F. Zannad (2013)
2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension.Journal of hypertension, 31 10
G. Tocci, A. Cicero, M. Salvetti, Pietro Francia, A. Ferrucci, Claudio Borghi, M. Volpe (2014)
Attitudes and preferences for the clinical management of hypertension and hypertension-related cardiac disease in general practice: results of the Italian Hypertension and Heart SurveyJournal of Human Hypertension, 29
H. Takagi, Y. Mizuno, Hirotaka Yamamoto, S. Goto, T. Umemoto (2013)
Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trialsHypertension Research, 36
A. Cicero, S. Ertek (2011)
Hypertension and diabetes incidence: confounding factorsHypertension Research, 34
G. Derosa, F. Querci, I. Franzetti, P. Ragonesi, A. D'Angelo, P. Maffioli (2015)
Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitusHypertension Research, 38
C. Borghi, A. Cicero (2012)
Hypertension: management perspectivesExpert Opinion on Pharmacotherapy, 13
C. Borghi, A. Cicero (2013)
How to avoid the depression of the adherence to antihypertensive treatment?Journal of hypertension, 31 7
M. Blüher, C. Mantzoros (2015)
From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century.Metabolism: clinical and experimental, 64 1
G. Mancia, G. Backer, A. Dominiczak, R. Cífková, R. Fagard, G. Germano, G. Grassi, A. Heagerty, S. Kjeldsen, S. Laurent, K. Narkiewicz, L. Ruilope, A. Rynkiewicz, R. Schmieder, H. Boudier, A. Zanchetti (2007)
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)Journal of Hypertension, 25
M. Michel, C. Foster, H. Brunner, Li-sheng Liu (2013)
A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor AntagonistsPharmacological Reviews, 65
D. Lemogoum (2014)
Challenge for Hypertension Prevention and Control Worldwide: The Time for ActionThe Journal of Clinical Hypertension, 16
Angela Price, I. Lingvay, Edward Szczepaniak, J. Wiebel, R. Victor, L. Szczepaniak (2013)
The metabolic cost of lowering blood pressure with hydrochlorothiazideDiabetology & Metabolic Syndrome, 5
Hypertension Research (2015) 38, 802–803 & 2015 The Japanese Society of Hypertension All rights reserved 0916-9636/15 www.nature.com/hr COMMENTARY Metabolic approaches to antihypertensive treatment in diabetic patients Arrigo F Cicero and Giuliano Tocci Hypertension Research (2015) 38, 802–803; doi:10.1038/hr.2015.105; published online 1 October 2015 ypertension management and control combination therapies, based on the use recommended by guidelines to be used in His still a major clinical challenge. of two or three pharmacological agents hypertensive patients at metabolic risk or in Despite the availability of modern diagnostic able to provide greater systolic/diastolic BP those with metabolic abnormalities, to pre- noninvasive options and effective, sustained reductions than each component used in vent development or reduce progression and well-tolerated pharmacological strategies, monotherapy and possibly additional, toward diabetes and its complications. pleiotropic beneficial effects on metabolic Finally, the proposed strategies are also the observational studies and national registries parameters. In particular, current guidelines one most used in clinical practice. have being continuously reported relatively recommended the use of combination At the end of the observation period, both poor rates of blood pressure (BP) control at therapies based on renin-angiotensin system treatments produced effective BP reductions, both national and local levels. Several poten- blocking agents,
Hypertension Research – Springer Journals
Published: Oct 1, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.